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In fibrotic livers, collagen producing hepatic stellate cells (HSC) represent a major target for antifibrotic therapies. We designed liposomes with
surface-coupled mannose 6-phosphate (M6P) modified human serum albumin (HSA) to target HSC via the M6P receptor. In this study we
determined the pharmacokinetics and target specificity of M6P-HSA-liposomes in a rat model of liver fibrosis. Ten minutes after injection of [3H]-
M6P-HSA-liposomes 90% of the dose has cleared the circulation. The blood elimination of these liposomes was counteracted by free M6P-HSA
and polyinosinic acid, a competitive inhibitor of scavenger receptors. The M6P-HSA-liposomes accumulated in HSC. However, also Kupffer cells
and endothelial cells contributed to the uptake of M6P-HSA-liposomes in the fibrotic livers. Polyinosinic acid inhibited the accumulation of the
liposomes in Kupffer cells and liver endothelial cells, but not in HSC. PCR analysis revealed that cultured HSC express scavenger receptors. This
was confirmed by Western blotting, although activation of HSC diminishes scavenger receptor protein expression. In conclusion, in a rat model for
liver fibrosis M6P-HSA-liposomes can be efficiently targeted to non-parenchymal cells, including HSC. M6P receptors and scavenger receptors are
involved in the cellular recognition of these liposomes, allowing multiple pharmacological interference in different pathways involved in the
fibrosis.
© 2007 Elsevier B.V. All rights reserved.Keywords: Hepatic stellate cells; Targeted liposomes; Liver fibrosis; Non-parenchymal cells; Mannose 6-phosphate receptor; Scavenger receptor1. Introduction
The potential of liposomes as a drug carrier system has been
extensively investigated. Various types of targeted liposomes
have been developed aiming at specific populations of liver
cells. Hepatocytes can be targeted using galactosylated lipo-
somes [1–3] or asialofetuin grafted vesicles [4]. Liposomes that
are modified with aconitylated human serum albumin predomi-⁎ Corresponding author. Department of Pathology and Laboratory Medicine,
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doi:10.1016/j.bbamem.2007.03.027nately accumulate in liver endothelial cells (LEC) [5] and
mannosylated liposomes are recognised by Kupffer cells (KC)
[6,7]. So far, no studies have been reported on targeting of
liposomes to hepatic stellate cells (HSC), which, in addition to
KC and LEC, comprise an important population of non-paren-
chymal cells in the liver.
In healthy organs, HSC are mainly responsible for storage of
vitamin A [8]. In diseased livers, HSC play a central role in the
processes that lead from chronic liver injury to fibrosis. Avariety
of factors including, chronic hepatitis B or C infections,
alcoholism and metabolic disorders, have been identified as
possible causes of liver fibrosis. In the initial stages of the
disease, damage to hepatocytes, biliary epithelial cells and other
hepatic cells induces the production of different factors by these
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endothelial cells (LEC) to release pro-inflammatory cytokines
[9]. Upon stimulation by these cytokines, HSC become activated
and transdifferentiate into myofibroblast-like cells. Activated
HSC are characterised by loss of vitamin A and a high rate of
proliferation [10]. Moreover, they migrate towards the site of
injury and produce excessive amounts of interstitial collagen,
mainly type I and III, which disposition leads to impairment of
liver structure and functions. HSC acquire also contractile
properties that allow them to control sinusoidal blood flow [11]
and contributing to the portal hypertension occurring in
cirrhotic patients. Liver fibrosis is a long-term disease which
is the most common non-neoplastic cause of death among
hepatobiliary and digestive diseases [12]. In addition, epide-
miological prognoses indicate that, in the coming years the
prevalence of liver fibrosis will significantly increase due to
increasingly occurring cases of hepatitis C infections [13] and
the rising number of patients with non-alcoholic steatohepatitis
[14]. So far no effective treatment has been established other
than removal of primary cause of the disease and liver
transplantation for severe fibrosis. Currently, a large variety of
drugs is being investigated for antifibrotic effects [12] which
can be classified according to their therapeutic effects, including
reduction of inflammation, antioxidant properties or promotion
of extracellular matrix degradation. Many of the compounds
aim at HSC to inhibit their activation and proliferation, reduce
ECM production by HSC, neutralize HSC contractile responses
or stimulate HSC apoptosis. Although, these compounds show
promising effects in vitro, the in vivo tests give disappointing
results, mainly due to the lack of cell specificity. Therefore, drug
carrier system targeted to the cells that are pivotal in the
development of fibrosis represent an attractive prospect for
future therapies.
In a rat model of liver fibrosis mannose 6-phosphate mo-
dified human serum albumin (M6P-HSA) was shown to
accumulate in HSC [15] and the uptake of this protein by
HSC was demonstrated to be mediated by mannose 6-phos-
phate/insulin like growth factor II (M6P/IGF II) receptor [16].
In fibrotic livers, HSC express an increased amount of the M6P/
IGF II receptor [17] that is involved in the activation of
transforming growth factor β (TGF-β) [18,19], a key profi-
brotic cytokine. Liposomes used as drug carriers in the anti-
cancer treatment have proven their potential in the therapy of
chronic disease. We designed a liposomal drug carrier to HSC
by coupling mannose 6-phosphate-modified human serum al-
bumin (M6P-HSA) to the surface of liposomes. Previously, we
demonstrated a high degree of association of M6P-HSA lipo-
somes with cultured HSC and we showed that these liposomes
can be targeted to HSC in fibrotic livers [20].
In the current in vivo studies, using bile duct ligated (BDL)
rats as a model of liver fibrosis, we determined the phar-
macokinetic properties and the biodistribution of M6P-HSA
liposomes in diseased animals. Subsequently, we analyzed
whether next to HSC, KC and LEC play a role in the accu-
mulation of M6P-HSA liposomes in BDL rats and tentatively
characterised the receptors responsible for the in vivo uptake of
these liposomes.2. Materials and methods
2.1. Chemicals
Cholesterol (Chol), N-succinimidyl-S-acetylthioacetate (SATA) and poly-
inosinic acid (poly I) were from Sigma (St. Louis MO, USA). 1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phos-
phoethanolamine-N-[4-(maleimidophenyl)butyramide] (MPB-PE) were pur-
chased from Avanti Polar Lipids (Alabaster AL, USA). [3H] cholesteryloleyl
ether (3H-COE) was obtained from Amersham Pharmacia Biotech (Buck-
inghamshire, UK). Human serum albumin fraction V was from Sanquin
(Amsterdam, The Netherlands). All other chemicals were of analytical grade or
the best grade available.
2.2. Animals
Specified pathogen free (SPF) male Wistar or Wag/Rij rats (Harlan, Horst,
The Netherlands) were housed under standard laboratory conditions with free
access to food and water. The presented studies were approved by the local
committee for care and use of laboratory animals.
2.3. Preparation of M6P-HSA
Human serum albumin N-substituted with mannose 6-phosphate (M6P)
groups was prepared and characterised as described before [15]. The average
number of M6P groups per albumin molecule was 29.
2.4. Preparation of liposomes
To prepare liposomes, appropriate volumes of POPC, CHOL and MPB-PE
stock solutions in chloroform/methanol (9:1) were mixed to obtain a molar ratio
23:16:1. When indicated the non-degradable bilayer marker, 3H-COE
(0.25 μCi/μmol total lipid) was added. Liposomes were prepared as described
before [21]. Briefly, organic solvent was evaporated under nitrogen, cyclohexan
was added and the lipid solution was lyophilised overnight. The dried powdery
lipids were hydrated in HN buffer (10 mM N-2-hydroxyethlpiperazine-N′-2-
ethanesulfonic acid (HEPES), 135 mM NaCl) pH 6.7 for 1 h at room
temperature. Liposomes were sized by extrusion through polycarbonate filters
(Whaterman, Maidstone, Kent, UK) of 50 nm pore size using high-pressure
extruder (Lipex, Vancouver, Canada). The phospholipid phosphorus content of
each liposome preparation was assessed by a phosphate assay [22]. The total
lipid concentration was calculated taking into account the amount of cholesterol
in the liposomal preparation. Size and size distribution were determined by
dynamic laser light scattering with a Nicomp submicron particle analyzer
(NICOMP 380 ZLS, Santa Barbara, CA, USA). The mean diameter of the
liposomes was obtained from the volume distribution curves produced by the
particle analyzer. Zeta potential of the particles was measured in demineralised
water (Nicomp 380). Liposomes without coupled protein were used in the
experiments as control liposomes. M6P-HSA prepared as described above was
coupled to MPB-PE liposomes by a sulfhydryl-maleimide coupling method
using SATA as a heterobifunctional reagent, as reported before for aconitylated
HSA [23]. Shortly, acetylthioacetate-M6P-HSA was separated from free SATA
by gel chromatography and deacetylated by freshly prepared solution of 0.5 M
hydroxylamine–HCl, 0.5 M HEPES and 25 mM EDTA, pH 7.0 added at the
ratio of 10 μl per 100 μl of protein solution. Next, thioacetyl-M6P-HSA was
incubated with MPB-PE containing liposomes for 4 h at room temperature at
the ratio of 0.3 mg of protein per 1 μmol of total lipid. The coupling reaction
was stopped by adding 8 mM N-ethylmaleimide (Sigma) solution in HN buffer
pH 7.4. Liposomes were purified from uncoupled M6P-HSA by flotation on
Opti-Prep™ (Axis-Shield PoCAS, Oslo, Norway) gradient. 2.5 ml of Opti-
Prep™ solution was mixed with 2 ml of incubation mixture containing
liposomes and protein and overlaid with 0.6 ml of HN buffer pH 7.4.
Liposomes were centrifuged (2 h at 40 000 rpm, 4 °C) and collected between
the buffer and the Opti-Prep™ layer after which the separation procedure was
repeated. M6P-HSA coupled liposomes were extensively dialysed against HN
buffer pH 7.4. Phospholipid phosphorus, protein content [24], particle size and
zeta-potential of M6P-HSA liposomes were analyzed again after protein
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after preparation.
Given the average diameter of M6P-HSA liposomes (R) and the total amount
of M6P-HSA coupled per μmol of total lipid (CMH), it is of interest to determine
the average number of M6P-HSA molecules coupled per liposome (ρ) as an
indicator of the possible significance of the coupling. If one assumes the
liposomes are approximately spherical with a diameter of R and the lipid is
contained within a shell with a thickness of dbl at the boundary of the liposome,
one can estimate this number by geometric arguments as
q R;CMHð Þ ¼ p6
CMHð3dblR2  3Rd2bl þ d3blÞ
MMHVLs
; ð1Þ
with VLs the specific volume of a lipid molecule andMMH the molecular mass of
M6P-HSA.
2.5. In vivo experiments
2.5.1. Animal model of liver fibrosis
Liver fibrosis was induced by bile duct ligation of male Wistar rats (500 g or
250 g) under anaesthesia with O2/N2O/Forene (isoflurane, Abbott Laboratories
Ltd., Queensborough, UK) according to standard procedures [25]. When
indicated, rats were used for in vivo experiments either 1 week (BDL-1) or
3 weeks (BDL-3) after bile duct ligation.
2.5.2. Blood disappearance and organ distribution
BDL-3 rats (250 g) were injected with 3H-COE labelled liposomes at a dose
of 1 μmol lipid per 100 g of body weight via the penile vein under O2/N2O/
Forene anaesthesia. When indicated, rats were injected with unlabelled M6P-
HSA or HSA (13 mg/kg of body weight) or poly I (16 mg/kg of body weight),
5 min before injection of liposomes. Blood samples were taken 5, 10, 20, 30 min
and 1 h after injection of liposomes. The total amount of radioactivity in the
serum was calculated using the equation [26]:
Vserum½ml ¼ 0:0219Mbody½g þ 2:66ml: ð2Þ
The pharmacokinetic parameters were calculated from measured serum
concentrations using the program Multifit [27]. The serum concentrations of
uncoupled liposomes were fitted to a mono-exponential function and the
appropriate pharmacokinetic parameters were derived. To calculate the
pharmacokinetic parameters for serum elimination of targeted liposomes, we
assumed that the preparation of the targeted liposomes contains small amounts of
uncoupled liposomes, which, after rapid clearance of targeted liposomes from the
blood, could be still detected in the serum samples for 1 h after injection.
Therefore the serum concentrations of the targeted liposomes were fitted to a bi-
exponential function and the pharmacokinetic parameters of the targeted
liposomes were derived from the fastest exponential, assuming that the
uncoupled liposomes were responsible for the slow second phase of the serum
disappearance profile.
At the last time point, rats were sacrificed and liver, spleen, kidneys, lungs
and heart were taken out for measurement of radioactivity as described before
[23].
2.5.3. HSC isolation
BDL-1 rats of 500 g were used to ensure harvesting of sufficient amounts of
HSC from the livers. Rats were injected with 3H-COE labelled liposomes at a
dose of 2 μmol lipid per 100 g of body weight via the penile vein under O2/N2O/
Forene anaesthesia and after 1 h HSC were isolated as described before [28].
Radioactivity associated with the isolated cells was determined by liquid
scintillation counting. The purity of the isolated HSC was assessed by
immunohistochemical staining with antibodies directed against specific markers
for HSC. Briefly, acetone/methanol (1:1) fixed cells were simultaneously incu-
bated with mouse monoclonal antibodies directed against desmin and α-smooth
muscle actin (both from Sigma). Endogenous peroxidase was inhibited with
H2O2 and cells were incubated, first with peroxidase conjugated rabbit-anti-
mouse IgG (Dako Cytomation, Denmark), and then with peroxidase conjugated
goat-anti-rabbit IgG (Dako). Antibody associated peroxidase was visualized
with 3-amino-9-ethyl-carbazole (AEC). Cells were counterstained with Mayer'shematoxylin. Positively stained cells were counted in ten microscopic fields,
magnification ×400 using Image J program (http://rsb.info.nih.gov/ij/).
2.5.4. Immunohistochemical analysis of liver sections
To identify the cells that bind M6P-HSA liposomes in fibrotic livers, M6P-
HSA liposomes at a dose of 2 μmol lipid per 100 g of body weight were injected
into BDL-3 rats (250 g) via the penile vein under O2/N2O/Forene anaesthesia.
When indicated, rats were injected with poly I (16 mg/kg of body weight), 5 min
prior to the administration of liposomes. Livers were harvested 20 min after
injection of liposomes, snap frozen in isopentane and stored at −80 °C until
further processing.
Cryostat sections of fibrotic livers (4 μm) were fixed in acetone. Im-
munohistochemical staining was performed as described earlier [15]. Briefly,
M6P-HSA liposomes were stained with a rabbit polyclonal antibody directed
against HSA (Cappel, Organon Teknika, Turnhout, Belgium). Endogenous
peroxidase was inhibited with H2O2 and sections were incubated, first with
peroxidase conjugated goat-anti-rabbit IgG (Dako Cytomation, Denmark), and
then with peroxidase conjugated rabbit-anti-goat IgG (Dako). Antibody asso-
ciated peroxidase was visualized with AEC. Sections were counterstained with
Mayer's hematoxylin.
When double immunostaining was performed, incubation of acetone fixed
liver sections with antibody directed against HSA was followed by incubation
with mouse monoclonal antibodies directed against cell proteins: desmin
(Cappel), ED2 (Serotec Oxford, UK) and HIS 52 (a kind gift from Prof G.
Molema UMCG, Groningen, The Netherlands) which are established markers
for HSC, KC and LEC, respectively. After inhibition of endogenous peroxidase
with H2O2 and incubation with two secondary peroxidase conjugated antibodies
for HSA detection as described above, liver sections were incubated with
alkaline phosphatase conjugated rabbit-anti-mouse IgG (Dako). Antibody-
associated alkaline phosphatase was visualized with Naphtol AS-MX/Fast Blue
(30 min at 37 °C) and peroxidase activity with AEC (10 min at RT).
2.6. Detection of M6P/IGF II receptor in healthy and fibrotic livers
2.6.1. RNA isolation and RT-PCR
Total RNA from liver tissue of healthy and BDL-3 rats was isolated using
RNeasy® Mini Kit (QIAGEN, Venlo, The Netherlands) according to the pro-
tocol of the manufacturer. RNAwas measured by NanoDrop® ND-1000 Spec-
trophotometer (Wilmington, DE, USA) and analysed qualitatively by gel
electrophoresis. Subsequently, synthesis of first strand cDNA from total RNA
(10 μg) was performed with SuperScript™ III RNase H-Reverse Transcriptase
(Invitrogen, Breda, The Netherlands) and 40 units RNaseOut inhibitor (Invi-
trogen) in a volume of 20 μl containing 250 ng random hexamers (Promega).
The cDNA thus obtained was diluted with Millipore water to a concentration of
10 ng/μl. For the PCR reaction, 10 μl of liver-homogenate cDNAwas applied in
a total volume of 30 μl containing 2× ReddyMix™ PCRMaster Mix (ABgene®,
UK) and 10 μM primers. Primers for M6P/IGF II rat receptor were designed
with the aid of Primer Designer from Scientific and Educational Software, based
on the mRNA sequence for the rat insulin like growth factor II receptor
(Accession number NM_012756). The sequence of M6P/IGF II receptor
primers was as follows: forward 5′-GTGTCCTCTGGGTGTGGACT-3′, reverse
5′-CTCCTCCTTGCTGACCTTTG-3′ (Genosys, Haverhill, UK), giving a
241 bp product.
GAPDH (forward 5′-ACGGAAGGCCATGCCAGTGA-3′, reverse 5′-
ACATGTTCCAGTATGACTCT-3′) (Biolegio BV, Nijmegen, The Netherlands)
was used as house keeping gene (590 bp product). Thirty cycles of reaction at
95 °C for 5 min, 95 °C for 30 s, 58 °C for 30 s, 72 °C for 30 s and 72 °C for 5 min
were carried out using the GeneAmp® PCRSystem 9700 (Applied Biosystem).
The polymerase chain reaction product was visualized on 1.5% agarose gel
containing ethidium bromide.
2.6.2. Immunohistochemical analysis of liver sections
Cryostat sections (4 μm) of livers from healthy and 3 weeks BDL rats were
fixed in acetone and incubated with a goat polyclonal antibody against M6P/IGF
II receptor (Santa Cruz Biotechnology, Inc.). Subsequently, endogenous pero-
xidase was inhibited with H2O2, followed by incubation with peroxidase
conjugated rabbit-anti-goat IgG (Dako) in the second step and with peroxidase
conjugated goat-anti-rabbit IgG (Dako) in the third. Antibody associated
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yer's hematoxylin.
2.7. Detection of SR-A expression by HSC
2.7.1. RNA isolation and RT-PCR
HSC were isolated from livers of male Wistar rats (550–600 g) as described
before [28]. Isolated HSC were cultured in DMEM containing 10% FCS, 100 U/
ml penicillin and 100 μg/ml streptomycin for 3 (quiescent phenotype) or 10 days
(activated phenotype). LEC and KC were isolated from livers of male Wag/Rij
rats (200–250 g) as described before [21]. LEC and KC were cultured in RPMI-
1640 medium supplemented with 20% FCS, 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin and in case of LEC 10 ng/ml endothelial cell
growth factor (Boehringer, Mannheim, Germany) for 2 days before being used
in the experiments.
Total RNA from cultured HSC was isolated using Absolutely RNA Micro-
prep kit (Stratagene, Amsterdam, The Netherlands) according to the protocol of
the manufacturer. Synthesis of cDNA from total RNA (200 ng–10 μg) was
performed as described above. cDNAwas diluted to the concentration of 10 ng/
μl. For PCR reaction, 1 μl of primary-cell cDNA and 10 μl of liver-homogenate
cDNAwas applied in a total volume of 30 μl containing 2× ReddyMix™ PCR
Master Mix (ABgene®). Primers for SR-A rat receptor were designed with the
aid of Primer Designer from Scientific and Educational Software, based on the
mRNA sequence for the rat scavenger receptor type A obtained from Genbank
(Accession number XM_573919). The sequence of SR-A primers was as
follows: forward 5′-ACTATAAATGGCTCCTCCGTTCA-3′, reverse 5′-AGA-
CTCTGCAAGGACTTGGAAAT-3′ (Biolegio BV), giving a 440 bp product.
GAPDHwas used as house keeping gene. For isolated cells 26 cycles of reaction
were carried out at 94 °C for 5 min, 94 °C for 30 s, 57 °C for 45 s, 72 °C for 45 s
and 72 °C for 7 min, and for liver homogenates 30 cycles were carried out using
the GeneAmp® PCRSystem 9700 (Applied Biosystem). The polymerase chain
reaction product was visualized on 1% agarose gel containing ethidium bromide.
2.7.2. Western blot
HSC and liver tissue from healthy and BDL-3 rats were homogenised in
lysis buffer (0.02 M Tris–HCl, 5 mM EDTA, 2 mM EGTA, 0.1 M NaCl, 0.05%
SDS, 0.5% NP-40, 10 μg/ml Protease Inhibitor Cocktail (Sigma)), separated by
10% polyacrylamide gel electrophoresis (30 μg protein of HSC per lane and
60 μg of liver homogenates per lane) and electroblotted onto nitrocellulose
membrane (Bio-Rad). SR-A (Santa Cruz Biotechnology Inc.) primary antibody
was used to detect scavenger receptor class A. Blots were developed using a
chemiluminescence detection system (Lumi-LightPLUS Western Blotting
substrate, Roche Diagnostic).
2.8. Statistical analysis
Statistical analysis of differences was performed by a two-tailed unpaired
Student's t-test. Differences were considered significant when pb0.05.Fig. 1. Blood disappearance of liposomes in BDL rats. Blood disappearance of
M6P-HSA liposomes (●,▾,▪) and control liposomes (○, ▵) in BDL rats that
were either untreated (●, ○) or preinjected with M6P-HSA (13 mg/kg of body
weight) (▾, ▵ ) or with HSA (13 mg/kg of body weight) (▪). 3H-COE labelled
liposomes were injected into BDL-3 rats at a dose of 1 μmol lipid per 100 g of
body weight, at indicated time points blood samples were taken and the
radioactivity was measured as described in Materials and methods. Data are
presented as means±SEM of 3 to 4 rats.3. Results
3.1. Blood elimination and organ distribution
Blood disappearance of M6P-HSA liposomes in fibrotic rats
3 weeks after bile duct ligation (BDL-3) was compared to that
of control liposomes of the same lipid composition but without
surface grafted M6P-HSA. The average diameter of injected
M6P-HSA liposomes was 102±13 nm and 46±15 μg (n=9) of
M6P-HSA was coupled per ìmol of total lipid. Combining Eq.
(1) with the literature values for the specific volume per lipid
molecule VLs (1.25 nm
3), the liposome bilayer thickness dbl
(3.7 nm) [29] and the molecular weight MMH of M6P-HSA
(about 69 kDa) [23], we estimated an average of around 31
molecules of M6P-HSA coupled per liposome. Control lipo-somes had a diameter of 80±2 nm (n=5). The charge of the
particles measured as zeta-potential was for M6P-HSA lipo-
somes −14.1±3.3 mV and for control liposomes −2.7±
2.2 mV. As early as 10 min after injection more than 90% of
the injected dose of M6P-HSA liposomes had disappeared
from the blood circulation, while of control liposomes only
45% had been cleared at that time point (Fig. 1). One hour after
injection, still 27% of all control liposomes were found in the
blood while M6P-HSA liposomes had disappeared almost
completely.
In order to study the specificity of the fast blood elimination
of M6P-HSA liposomes in BDL rats, free M6P-HSA was in-
jected into rats prior to administration of liposomes. Blood
clearance of M6P-HSA liposomes was significantly attenuated
by an excess of M6P-HSA (Fig. 1). This resulted in an increase
in the half life (t1/2) of M6P-HSA liposomes in the circulation
and in a decrease in the plasma clearance (CL) in M6P-HSA
pre-treated rats (Table 1). An excess of M6P-HSA had no effect
on the blood elimination of control liposomes. When BDL rats
were injected with free HSA prior to the M6P-HSA liposome
administration, the blood disappearance of these liposomes was
not influenced (Fig. 1), (Table 1).
The organ distribution of M6P-HSA liposomes in BDL rats
was determined 1 h after injection of liposomes. At this time
point 71.0±3.5% of the injected dose of M6P-HSA liposomes
had been taken up by the liver. The spleen accounted for 2.6±
0.2% of the injected dose of M6P-HSA liposomes, while the
lungs contained 3.2±0.6%. In other organs examined (heart and
kidneys) uptake of M6P-HSA liposomes was less than 1%.
Table 1




V [ml/kg] AUC(0–∞ min)
[min μmol/ml]
M6P-HSA liposomes 2.6±0.2 4.0±0.1 59.9±7.5 2.6±0.1
+M6P-HSA 43.6±7.4 1.1±0.1 67.1±5.7 9.4±1.1
+HSA 1.9±0.3 3.9±0.2 81.8±25.1 2.5±0.1
Control liposomes 46.1±1.5 0.65±0.01 43.5±0.7 15.3±0.3
+M6P-HSA 42.8±2.2 0.71±0.02 43.5±1.2 14.2±0.5
3H-COE labelled M6P-HSA liposomes and control liposomes were adminis-
tered at a dose of 10 μmol lipid/kg body weight into anaesthetized BDL-3 rats.
M6P-HSA or HSA (13 mg/kg of body weight) was injected 5 min before M6P-
HSA liposomes. Blood samples were taken 5, 10, 20, 30 and 60 min after
administration of liposomes and analyzed as described in Materials and
methods. Data are inferred from fits over the mean of 3 rats±SE. t1/2, half time;
CL, plasma clearance; V, volume of distribution; AUC, area under the fitted
concentration–time curve.
Fig. 2. Organ distribution of liposomes in BDL rats. Shown are control
liposomes (empty) and M6P-HSA liposomes with (shaded) and without (filled)
a pre-injection of free M6P-HSA (13 mg per kg of body weight, injected 5 min
before). 3H-COE labelled liposomes were injected into BDL-3 rats at a dose of
1 μmol lipid per 100 g of body weight. One hour after injection of the liposomes
the tissue distribution was determined as described in Materials and methods.
Data are presented as means±SEM of 3 rats, *pb0.05; ***pb0.001.
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1.2% of the dose), but 50% less uptake was observed in the liver
when compared to M6P-HSA liposomes (Fig. 2).
In rats preinjected with free M6P-HSA, liver uptake of M6P-
HSA liposomes was 15% lower than in untreated rats while
increased accumulation of M6P-HSA liposomes was observed
in lungs of M6P-HSA pre-injected rats (Fig. 2).
3.2. Cellular localisation of M6P-HSA liposomes in fibrotic
livers
Previously, we demonstrated in vitro that expression of the
M6P/IGF II receptor in activated HSC increases compared to
that in quiescent cells, both on the mRNA and the protein level
[20]. In order to confirm these data, the in vivo expression of the
M6P/IGF II receptor in the fibrotic liver was compared to that in
the healthy organ (Fig. 3). The PCR analysis showed that
expression of the M6P/IGF II receptor in livers of BDL rats is
high compared to expression in the livers of healthy rats.
Immunohistochemical analysis of liver sections revealed that
this receptor is predominantly expressed on hepatocytes in the
control livers, whereas, in the livers of BDL-3 rats, positively
stained cells with spindle-shape nuclei were observed in areas
affected by disease. Together with our previous observations in
vitro, these data demonstrate that HSC in the fibrotic liver
express the M6P/IGF II receptor.
The localisation of M6P-HSA liposomes was determined in
livers of BDL-3 rats using immunohistochemical methods. The
morphological appearance of the immunostaining pattern
observed following injection of M6P-HSA liposomes, with an
antibody directed against HSA, indicated that these liposomes
accumulate in non-parenchymal cells (Fig. 4A) and were mainly
distributed in the areas containing relatively low amounts of
collagen (data not shown). By double-immunostainings we
subsequently determined which of the non-parenchymal cell
types contribute to the uptake of M6P-HSA liposomes. Liver
sections were simultaneously stained for HSA and cell-specific
markers for KC (ED 2), LEC (HIS 52) or HSC (desmin).
Immunohistochemical analysis revealed that M6P-HSA lipo-somes co-localised with HSC (Fig. 4B), LEC (Fig. 4C) as well as
with KC (Fig. 4D).
In addition, to quantify the uptake of M6P-HSA liposomes in
HSC in fibrotic livers, these cells were isolated from BDL-1 rats
injected with radioactively labelled liposomes. Uptake of M6P-
HSA liposomes in HSC-enriched fractions was almost 7-fold
that of control liposomes (Fig. 4E). 70% of the cells in the HSC-
enriched cell fraction were HSC, while KC and LEC accounted
for the remainder of the cells in this HSC fraction, as assessed
by immunohistochemical staining against ED2 and HIS 52
(data not shown).
3.3. Effect of polyinosinic acid on blood elimination and
intrahepatic distribution of M6P-HSA liposomes in BDL rats
The uptake of M6P-HSA liposomes by cultured HSC is
mediated by M6P/IGF II receptors and most likely also by
scavenger receptors (ScR) [20]. Firstly, the M6P/IGF II receptor
can recognise the M6P moieties of the modified albumin.
Secondly, the phosphate residues of the sugar group confer
multiple negative charges to M6P-HSA while positive charges
of albumin are cancelled out. The polyanionic character of the
molecule may classify it as a ligand for ScR class A. We
hypothesised that accumulation of M6P-HSA liposomes in LEC
and KCmay be mediated through ScR class A, since they do not
express significant levels of M6P/IGF II receptor [18,30] but are
known to express different types of ScR, including ScR class A
[31]. To examine this, 5 min prior to injection of M6P-HSA
liposomes, poly I, which is a competitive inhibitor of ScR class
A [32] was injected into BDL-3 rats. Blood elimination of
liposomes was strongly inhibited in the poly I treated rats,
compared to untreated animals (Fig. 5G). As a result, t1/2 of
M6P-HSA liposomes was significantly increased and CL
Fig. 3. Expression of M6P/IGF II receptor in livers of BDL rats. M6P/IGF II receptor expression was determined in the healthy and BDL-3 livers at the mRNA level
using RT-PCRwith GAPDH as a house keeping gene (A) as described inMaterials and methods. Protein expression of M6P/IGF II receptor was assessed in the healthy
(B) and BDL-3 (C) livers by immunohistochemical staining as described in Materials and methods. Original magnification ×400. Arrows indicate positively stained
cells.
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that were not pre-injected with poly I (Table 1). Immunohis-
tochemical analysis of liver sections, 20 min after injection of
M6P-HSA liposomes, revealed a distinct inhibition of the
uptake of these liposomes by poly I in the liver that, however,
did not lead to an increased uptake of liposomes elsewhere (data
not shown). Further investigations into the cell types respon-
sible for the uptake of M6P-HSA liposomes in poly I treated rats
showed that accumulation of these liposomes in KC (Fig. 5A,
B) and LEC (Fig. 5C, D) is strongly inhibited by poly I. We did
not observe a prominent difference in the uptake of M6P-HSA
liposomes by HSC between poly I treated and untreated rats
(Fig. 5E, F).
The expression of ScR class A by quiescent HSC (qHSC)
and activated HSC (aHSC) was checked at the mRNA and
protein level. In qHSC and aHSC levels of ScR class A mRNA
were comparable to that of KC and LEC (Fig. 6A). However,
Western blot analysis showed that qHSC abundantly express
ScR class A while this protein was absent in aHSC (Fig. 6B).
ScR class A could also be detected in liver homogenates of
healthy and fibrotic organs. The ratio of ScR class A to β-actin
used as house keeping protein for qHSC was 0.72 while for
aHSC 0.002.
4. Discussion
In the present study we characterised the targeting properties
of M6P-HSA liposomes in a rat model of liver fibrosis induced
by bile duct ligation. We showed that M6P-HSA liposomes are
rapidly cleared from the blood circulation in diseased rats and
mainly accumulate in the liver. This fast elimination of M6P-HSA liposomes from the blood by the target organ and the
limited accumulation in other organs demonstrate that the organ
distribution profile of M6P-HSA liposomes is highly suitable to
deliver drugs to a diseased liver. The prolonged blood circulation
time of M6P-HSA liposomes in animals treated with M6P-HSA
in combination with lung injury that has been reported in BDL
rats may have caused increased lung uptake in these rats [33].
Particularly, the development of pulmonary intravascular
macrophages (PIM) in the lungs of BDL rats may play a role
in this elevated accumulation. Similarly, a shift in uptake from
the liver to the lungs caused by PIM was observed in BDL rats
injected with adenoviral particles [34,35]. The rapid blood
clearance of M6P-HSA liposomes was blocked by pre-injection
of M6P-HSA, but not by HSA, indicating a specific recognition
of mannose 6-phosphate groups by cells within the liver.
In the livers of BDL rats (biliary fibrosis), collagen depo-
sition predominately surrounds the proliferating bile ducts and
to a lesser extent is localized in zones 1 and 2 (central vein and
periportal area) of the liver [12]. M6P-HSA liposomes mainly
distribute to zones 1 and 2 i.e. the areas containing relatively
low amounts of collagen. The regions of the liver characterized
by massive deposition of extracellular matrix proteins were
clearly less accessible to liposomes. Changes in the hepatic
architecture associated with fibrosis most likely interfere with
the distribution of M6P-HSA liposomes within the liver. In the
healthy liver, endothelial cells are fenestrated with pores of 150
to 175 nm in diameter [36] , that enable a close contact between
blood and the space of Disse where HSC are situated. In the
fibrotic liver, endothelial cells at least partly lose their fenes-
trations [37] and, in addition, the contraction of HSC causes an
increased vascular resistance in the sinusoids [11]. As a result,
Fig. 4. Intrahepatic distribution of M6P-HSA liposomes in livers of BDL rats. M6P-HSA liposomes taken up by the liver were immunohistochemically stained with a
specific antibody directed against HSA (A, red staining) as described in Materials and methods. Identification of the liver cells responsible for M6P-HSA liposome
uptake was done by double immunostaining using antibodies directed against HSA (red staining) to detect M6P-HSA liposomes and against specific cell markers (blue
staining) to identify either HSC (desmin, B), LEC (HIS 52, C) or KC (ED 2, D). Arrows indicate double positive cells, original magnification of A ×100, of B, C, D
×400; cv, central vein. (E) Uptake of M6P-HSA liposomes and control liposomes in HSC enriched cell fractions isolated from fibrotic livers was determined 1 h after
injection of 3H-COE labelled liposomes into BDL-1 rats at a dose of 2 μmol lipid per 100 g of body weight. HSC were isolated from the livers and the radioactivity was
measured as described in Materials and methods. Data are presented as means±SD of 3 experiments, *pb0.05.
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sible to macromolecules. The size of M6P-HSA liposomes (ap-
proximately 100 nm) allows them to pass fenestrations in
endothelial cells in those parts of the fibrotic livers where they
are still present and functional.
The high accumulation of M6P-HSA liposomes compared to
control liposomes in HSC-enriched fractions isolated from BDL
rat livers demonstrates that M6P-HSA liposomes are taken upby HSC in fibrotic livers. These data are in agreement to our
previous study in which we demonstrated a 3,5-fold higher
uptake of M6P-HSA liposomes as compared to control lipo-
somes in cultured activated HSC [20].
Immunohistochemical examination revealed that M6P-HSA
liposomes also accumulate in two other major non-parenchymal
cells populations: liver endothelial cells (LEC) and Kupffer cells
(KC). It is known that activated HSC express an increased
Fig. 5. Effect of poly I on the intrahepatic distribution of M6P-HSA liposomes in
livers of BDL rats. Photomicrographs show an overview of liver sections of
BDL-3 rats, treated (B, D, F) or untreated (A, C, E) with poly I (16 mg/kg of
body weight) before injection of M6P-HSA liposomes (2 μmol lipid per 100 g of
body weight). Sections were double immunostained using antibodies directed
against HSA (red staining) to detect M6P-HSA liposomes and against specific
cell markers (blue staining) to identify KC (ED2, A and B), EC (HIS 52, C and
D) and HSC (desmin, E and F). Original magnification ×200. Note the reduced
HSA/ED2 and HSA/HIS 52 double staining in poly I-treated rats compared to
untreated rats (A vs. B, C vs. D), whereas HSA/desmin double staining is not
affected by poly I injection (E vs. F). (G) Effect of poly I on blood elimination
and the pharmacokinetics of M6P-HSA liposomes in BDL-3 rats. 3H-COE
labelled M6P-HSA liposomes were administered at a dose of 10 μmol/kg body
weight into anaesthetized BDL-3 rats. Poly I (16 mg/kg of body weight) was
injected 5 min before M6P-HSA liposomes. Blood samples were taken at
indicated time points and analyzed as described in Materials and methods. Data
of blood elimination of M6P-HSA liposomes in poly I treated rats are presented
as means±SEM of 3 rats. Pharmacokinetic parameters of M6P-HSA liposomes
in poly I treated rats were inferred from fits over the mean of 3 rats and given as
±SE. t1/2, half life; CL, plasma clearance; V, volume of distribution; AUC, area
under the fitted concentration–time curve.
Fig. 6. Expression of scavenger receptor class A by cultured HSC. mRNA
expression of ScR class A (ScR-A) by quiescent HSC (qHSC, 3-day cultured)
and activated HSC (aHSC, 10-day cultured) was determined using RT-PCR with
GAPDH as a house keeping gene (A). Primary Kupffer cells (KC), liver
endothelial cells (LEC) as well as liver homogenates of healthy and BDL-3 rats
were positive controls. Protein expression of ScR-A by qHSC and aHSC was
assessed byWestern blotting (B). Total liver homogenates of healthy and BDL-3
rats were used as positive controls.
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ficant levels of M6P/IGF II receptor expression were observed
on LEC [18] and KC [30]. Therefore, in the recognition of M6P-
HSA liposomes by KC and LEC scavenger receptors (ScR)
might be involved. ScR are known to bind anionic (macro)
molecules and are abundantly expressed by KC and LEC. Thecurrent study showed that polyinosinic acid (poly I), an es-
tablished competitive inhibitor of ScR class A, strongly pre-
vented the rapid blood clearance of M6P-HSA liposomes and
exerted an inhibitory effect on the association of these liposomes
with KC and LEC in fibrotic livers. Uptake of M6P-HSA lipo-
somes by HSC was still observed in poly I treated rats (Fig. 5F),
which indicates that liposomes are recognised by other types of
receptors on these cells, in particular M6P/IGF II receptors.
However, we cannot exclude the presence of scavenger
receptor class A on HSC. We reported before, that cultured HSC
take up liposomes modified with polyanionic albumin, aco-
nitylated HSA and that this process can be inhibited by poly I
[20]. In the present study, we demonstrated that at the mRNA
level ScR class A was present in both quiescent and activated
HSC while at the protein level the expression of ScR class A
decreased in the activated cells. The molecular weight of ScR
class A found in the Western blot analysis was slightly lower
(64 kDa) than indicated by manufacturer of the antibody
(75 kDa). However, different molecular masses (72 and 65 kDa)
of mature bovine ScR class A type II receptor have been
reported [38]. Although M6P/IGF II receptors and scavenger
receptors considerably contribute to the uptake of M6P-HSA
liposomes, involvement of other receptors cannot be ruled out.
The development of liver fibrosis is a complex process, in
which different types of cells are involved. The initial step, the
impairment of hepatocytes, results in the release of reactive
oxygen species and fibrotic and inflammatory cytokines stimu-
lating in turn KC, LEC and HSC, as well as in recruitment of
cells of the immune system. KC, LEC and inflammatory cells
further promote activation of HSC, leading to transformation of
these cells into an activated phenotype characterised by a high
proliferation rate, production of collagen and mediators of
fibrosis, which in an autocrine manner maintain the activated
status of stellate cells [10]. The uptake of M6P-HSA liposomes
by KC and LEC, next to the uptake in HSC has to be taken into
account when an antifibrotic drug is chosen for encapsulation
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of collagen in the fibrotic liver, specific inhibitors of its
production which are not harmful for KC and LEC would seem
to be suitable candidates for incorporation into M6P-HSA lipo-
somes. However, the multiple targeting properties of M6P-HSA
liposomes to all relevant regulatory cells of the fibrotic process
offer the possibility to deliver simultaneously anti-inflammatory
drugs to KC and LEC and antifibrotic compounds to HSC in the
diseased liver. Currently, there are several known compounds
which could be possibly used in this approach. Antioxidants
such as quercetin and resveratrol inhibit proliferation and acti-
vation of HSC, and in addition decrease the production of nitric
oxide (NO) and tumor necrosis factor α (TNF-α) by KC [39].
Alternatively, thiazolidinediones, which are peroxisome pro-
liferator-activated receptor-γ agonists, inhibit HSC collagen
production [40] as well as proliferation and chemotaxis of these
cells [41]. In KC, these compounds reduce TNF-α and NO
production [42]. This strategy for attenuation of liver fibrosis
may be efficient, since the complexity of the disease suggests
that a simultaneous interference with multiple pathways of the
fibrotic process in different cell types may be the most success-
ful antifibrotic approach.
In conclusion, we have shown that liposomes coupled with
M6P-HSA are potentially effective drug carriers, targeted to the
non-parenchymal cells, including HSC, which play a crucial
role in the development of liver fibrosis. The recognition of
M6P-HSA liposomes by HSC, LEC and KC in the fibrotic liver
is M6P-HSA specific, involving both M6P/IGF II and sca-
venger receptors. The multiple targeting properties of M6P-
HSA liposomes open up new possibilities for pharmacological
interference with a disease as complex as liver fibrosis.
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